Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model

International Journal of Cancer

Volumn 98, Issue 2, 2002, Pages 297-309

  Lokeshwar, Bal L ^a,c   Selzer, Marie G ^a   Zhu, Bao Qian ^a   Block, Norman L ^a   Golub, Lorne M ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Chemically modified tetracyclines; COL 3; Metalloproteinase inhibitors; Metastasis; Prostate cancer; Tetracycline; Therapeutics

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; DOXYCYCLINE; GELATINASE A; HYDROXYL RADICAL; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER INVASION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DEPOLARIZATION; DRUG EFFICACY; HUMAN; HUMAN CELL; LUNG METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; HYDROXYL RADICAL; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; RATS; TETRACYCLINES; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR CELLS, CULTURED;

EID: 0037051090     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10168     Document Type: Article

References (77)

1. Hormone refractory prostate cancer: National comprehensive cancer network guidelines
2. One hundred thirteen men with hormone-refractory prostate cancer died today
3. Principles of molecular cell biology of cancer: Cancer metastasis
4. Tumor cell interactions with the extra cellular-matrix during invasion and metastasis
5. Steps in tumor metastasis: New concepts from intravital videomicroscopy
6. Mechanism of tumor invasion and metastasis
7. Metalloproteinase and cancer invasion
8. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
9. Matrix metalloproteinases: Multifunctional contributors to tumor progression
10. Secretion of matrix metalloproteinase and their inhibitors (TIMPs) by human prostate in explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues
11. Expression of metalloproteinase genes inhuman prostate cancer
12. Type IV collagenase (Mr 72,000) expression in human prostate: Benign and malignant tissue
13. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinase
14. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
15. Diversity of melanoma plasma membrane proteinases: Inhibition of collagenolytic and cytolytic activities by minocycline
16. The mitochondrial genetic system as a target for chemotherapy: Tetracycline as cytostatic
17. Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs
18. Inhibition of tumor angiogenesis
19. Host modulation with tetracyclines and their chemically modified analogues
20. Arrest of the proliferation of renal and prostate carcinomas of human origin by inhibition of mitochondrial protein synthesis
21. A non-antibacterial chemically modified tetracycline inhibits mammalian collagenase activity
22. HPLC determination of a chemically modified non-antimicrobial tetracycline: Biological implications
23. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel micro titer assay for inhibitors
24. Matrix metalloproteinases and their inhibition in periodontal treatment
25. In vitro sensitivity of three mammalian collagenases to tetracycline inhibition: Relationship to bone and cartilage degradation
26. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers
27. Enhancement of radiation response of prostatic carcinoma by taxol: Therapeutic potential for late-stage malignancy
28. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1
29. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
30. Expression of CD44 in prostate cancer cells: Association with cell proliferation and invasive potential
31. A new method for cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′- tetraethylbenzimidazol carbocyanine iodide (JC-1)
32. Cytotoxic activity and inhibition of tumor cell invasion by derivatives of a chemically modified tetracycline CMT-3
33. Flow cytometric detection of hydrogen peroxide production induced by doxorubicin in cancer cells
34. A sensitive flow cytometric method for measuring the oxidative burst
35. Rapid DNA content analysis by propidium iodide-hypotonic citrate method
36. Theoretical aspects of flow cytometry data analysis
37. A rapid in vitro assay for quantitating the invasive potential of tumor cells
38. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines
39. 3H-acetylated collagen
40. Determination of metalloproteinase activity after selective destruction of tissue inhibitor of metalloproteinases
41. Matrix metalloproteinase and their inhibitors in connective tissue remodeling
42. Free radical formation by ansymicin benzoquinone in human breast tumor cells: Implication for cytotoxicity resistance
43. Mechanisms involved in chemotherapy induced-apoptosis and their implications in cancer chemotherapy
44. Antimicrobial agents: Tetracyclines, chloramphenicol, erythromycin, and miscellaneous antibacterial agents
45. Studies on succinate-tetrazolium reductase systems
46. The biochemical and cellular basis of cell proliferation assays that uses tetrazolium salts
47. MMP inhibition in prostate cancer
48. Iron-chelating activity of tetracyclines and its impact on the susceptibility of actinobacillus actinomycetemcomitans to these antibiotics
49. The mitochondrial permeability transition in cell death: A common mechanism in necrosis, apoptosis and autophagy
50. Calcium-dependent and calciumindependent mechanisms of irreversible cell injury in cultured hepatocytes
51. Reactive oxygen species (ROS)-induced ROS-release: A new phenomenon accompanying induction of mitochondrial permeability transition in cardiac myocytes
52. Pre-clinical dose range-finding studies of COL-3 (NSC-683551) in rats and monkeys
53. CDK inhibitors: Positive and negative regulators of G1-phase progressions
54. Interleukin 10 (IL-10) Inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion
55. Plasminogen activator activity is decreased in rat gingiva during diabetes
56. Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: Association with reduced cancer cell migration
57. Influence of chemically modified tetracyclines on proliferation, invasion, and migration properties of MDA-MB468 human breast cancer cells
58. Angiogenesis inhibition by minocycline
59. Antiangiogenic agents potentiate cytologic cancer therapies against primary and metastatic disease
60. An experimental model stimulating local recurrence and pelvic lymph node metastasis following orthotopic induction of prostate cancer
61. Effects of tetracyclines on angiogenesis in vitro
62. Inhibitory effects of minocycline on in vitro invasion and experimental metastasis of mouse renal adenocarcinoma
63. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis
64. Effects of doxycycline on human prostate cancer cells in vitro
65. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
66. Matrix metalloproteinase inhibitors: A novel class of anticancer agents
67. Effect of metalloproteinase inhibitor Batimastat on breast cancer regrowth and metastasis in athymic mice
68. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice
69. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
70. Ongoing trials with matrix metalloproteinase inhibitors
71. Cancer metastasis: A search for therapeutic inhibition
72. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A) in patients with advanced solid tumor
73. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
74. MMP inhibition in prostate cancer